+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hematology Drugs Market Global Briefing 2018

  • ID: 4452387
  • Report
  • Region: Global
  • 31 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Bayer AG
  • Biogen Inc.
  • Daiichi Sankyo Company
  • Limited
  • Novo Nordisk A/S
  • Pfizer Inc
  • MORE
North America was the largest region in the hematology drugs market in 2017, accounting for around 40% market share. This can be attributed to established healthcare market coupled with nationwide health insurance coverage in countries such as the USA and Canada. Western Europe was the second largest region accounting for around 20% market share. Asia Pacific was the third largest region accounting for around 18% market share.

Hematology Drugs Market Global Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global hematology drugs sector.

Reasons to Purchase:
  • Fully updated for 2018.
  • Identify growth segments and opportunities.
  • Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
  • Develop strategies based on likely future developments.
  • Gain a global perspective on the development of the market.
Description

Hematology Drugs Market Global Briefing 2018 covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the hematology drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the hematology drugs market and suggests approaches.

Scope:

Markets Covered: Blood Products, Anemia and Other Blood Disorder Drugs.
Companies Mentioned: Novo Nordisk A/S, Shire Plc., Bayer AG, Daiichi Sankyo Company Limited, Biogen Inc., Pfizer Inc.
Geographic Scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa
Time Series: Five years historic and forecast.
Data: Market value in $ billions.
Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • Biogen Inc.
  • Daiichi Sankyo Company
  • Limited
  • Novo Nordisk A/S
  • Pfizer Inc
  • MORE
Hematology Drugs Market Characteristics
Hematology Drugs Market Historic Growth (2013 - 2017)
Hematology Drugs Market Forecast Growth (2017 - 2021)
Hematology Drugs Market Segmentation
Global Hematology Drugs Market, Split by Segments, 2017, $ Billion
Blood Products
Anemia and Other Blood Disorder Drugs
Global Hematology Drugs Market, Historic and Forecast, Split by Segments, 2013 - 2021
Hematology Drugs Market Geography Regional and Country Comparison
Global Hematology Drugs Market, Split by Regions, 2017
Global Hematology Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Global Hematology Drugs Market, Split by Country, 2017
Global Hematology Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Hematology Drugs Market Competitive Landscape
Novo Nordisk A/S
Shire Plc
Bayer AG
Daiichi Sankyo Company, Limited
Biogen Inc
Pfizer Inc
Novo Nordisk
Shire Plc
Bayer AG
Hematology Drugs Market Key Mergers and Acquisitions
Sumitomo Dainippon Pharma Co. Ltd. Acquired Tolero Pharmaceuticals
Novartis Acquired Selexys Pharmaceuticals Corporation and SelG1 Antibody
Miragen Therapeutics, Inc. Merged With Signal Genetics, Inc
RXi Pharmaceuticals Acquired MirImmune Inc
Sorrento Therapeutics, Inc., Merged With Yuhan Corporation
Hematology Drugs Market Trends and Strategies
Tranexamic Acid To Prevent Postpartum Hemorrhage
Increase in Product Approvals for Hemophilia
Gene Therapy For Treatment of Sickle-Cell Disease
Genetically Engineered Drug For Von Willebrand Disease (VWD)
Appendix
NAICS Definitions of Industry Covered in This Report
Definition of Market Covered in This Report
Abbreviations
Currencies
Research Methodology
Research Inquiries
About the Publisher

List of Figures
Figure 1: Global Hematology Drugs Market, Historic Market Size, 2013 - 2017, $ Billion
Figure 2: Global Hematology Drugs Market, Forecast Market Size, 2017 - 2021, $ Billion
Figure 3: Global Hematology Drugs Market, Split by Segments, 2017, $ Billion
Figure 4: Global Hematology Drugs Market, Historic and Forecast, Split by Segment, 2013 - 2021
Figure 5: Global Hematology Drugs Market, Split by Region, 2017, $ Billion
Figure 6: Global Hematology Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Figure 7: Global Hematology Drugs Market, Split by Country, 2017, $ Billion
Figure 8: Global Hematology Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Figure 9: Global Hematology Drugs Market, Key Competitor Estimated Market Shares, 2017, Percentage (%)

List of Tables
Table 1: Global Hematology Drugs Market, Historic Market Size, 2013 - 2017, $ Billion
Table 2: Global Hematology Drugs Market, Forecast Market Size, 2017 - 2021, $ Billion
Table 3: Global Hematology Drugs Market, Split by Segments, 2017, $ Billion
Table 4: Global Hematology Drugs Market, Historic and Forecast, Split by Segment, 2013 - 2021
Table 5: Global Hematology Drugs Market, Split by Region, 2017, $ Billion
Table 6: Global Hematology Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Table 7: Global Hematology Drugs Market, Split by Country, 2017, $ Billion
Table 8: Global Hematology Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Table 9: Global Hematology Drugs Market, Key Competitor Estimated Market Shares, 2017, Percentage (%)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Bayer AG
  • Biogen Inc.
  • Daiichi Sankyo Company
  • Limited
  • Novo Nordisk A/S
  • Pfizer Inc
  • MORE
Hematology drugs market offers drugs, blood and blood products that are used for the treatment of diseases such as rare genetic disorders, anemia, and conditions related to sickle cell disease and other related diseases. Some of the major hematology drugs include Albumin, Epoetin, Zoladex, and Hyskon.

North America was the largest region in the hematology drugs market in 2017, accounting for around around 40% market share. This can be attributed to established healthcare market coupled with nationwide health insurance coverage in countries such as the USA and Canada. Western Europe was the second largest region accounting for around around 20% market share. Asia Pacific was the third largest region accounting for around around 18% market share.

Tranexamic Acid to Prevent Postpartum Hemorrhage - Tranexamic acid is increasingly being used to prevent postpartum hemorrhage (blood loss of over 500 ml or 1,000 ml within 24 hours of childbirth) due to its cheap price and wide availability. Tranexamic acid is an antifibrinolytic drug that helps in reducing bleeding in surgical and trauma patients, including women with postpartum hemorrhage. in April 2017, WOMAN (World Maternal Antifibrinolytic), an international, randomized, double-blind, placebo-controlled trial including over 20,000 women from 193 hospitals in 21 countries, found that using tranexamic acid within three hours of childbirth lowered death from bleeding by 31% and reduced the need for laparotomy (emergency bleeding control surgery) by 36%, as compared to placebo.
Note: Product cover images may vary from those shown
5 of 5
  • Novo Nordisk A/S
  • Shire Plc.
  • Bayer AG
  • Daiichi Sankyo Company
  • Limited
  • Biogen Inc.
  • Pfizer Inc
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4452387
Adroll
adroll